Table 2 Five dose-toxicity scenarios that are considered for the design evaluation. Note, we present the risk of DLT at reach dose here, rather than additional risk of DLT
From: Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic
d0 | d1 | d2 | d3 | d4 | |
|---|---|---|---|---|---|
Scenario 1 | 10% | 30% | 45% | 60% | 70% |
Scenario 2 | 10% | 15% | 30% | 45% | 60% |
Scenario 3 | 10% | 12% | 15% | 30% | 45% |
Scenario 4 | 10% | 11% | 12% | 15% | 30% |
Scenario 5 | 10% | 50% | 65% | 80% | 90% |